alto-207
Generic: pramipexole and ondansetron·Code: CTC-501
alto-207: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Alto Neuroscience, Inc. (ANRO) | Phase 2 |
FDA Decisions
FDA_MeetingCompany reported a successful FDA meeting outcome and plans to accelerate development of ALTO-207 for treatment-resistant depression.(ANRO)
Frequently asked questions
Who is developing alto-207?
alto-207 is being developed by Alto Neuroscience, Inc..
What is alto-207's latest FDA decision?
The most recent tracked FDA decision for alto-207 is FDA_Meeting for Company reported a successful FDA meeting outcome and plans to accelerate development of ALTO-207 for treatment-resistant depression..
Get deeper analysis on alto-207
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis